Corcept Therapeutics Incorporated (CORT) — Quality & forensics
As of 2026-11-17 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 32
- Quality 66
- Growth 72
- Balance sheet 89
- Cash quality 54
- Capital allocation 42
- Momentum 51
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the CORT chart & overview · the earnings record
FAQ · from the current data · as of 2026-11-17
Quick answers
What is Corcept Therapeutics Incorporated's Closelooknet quality reading?
The composite reads 60/100 across 7 modules, as of 2026-11-17: valuation 32, quality 66, growth 72, balance sheet 89, cash quality 54, capital allocation 42, momentum 51. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Corcept Therapeutics Incorporated's Altman Z-Score?
28.71, which sits in the safe zone (above 2.99) as of 2026-11-17. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Corcept Therapeutics Incorporated's Piotroski F-Score?
4 of 8, as of 2026-11-17. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Corcept Therapeutics Incorporated's Beneish M-Score indicate?
-2.75 — below the −1.78 manipulation-risk threshold, as of 2026-11-17. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Mentioned on Closelooknet
Where CORT appears in the diary — 1 piece, newest first. Every link is our own writing.
Go deeper
Dailies
- A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000
Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG…
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- ARGX.BR Argen-Xindustry
- RIGL Rigel Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- SLS Sellas Life Sciences Group Incindustry
- REPL Replimune Group Incindustry
- VCEL Vericel Corp Ordindustry
- VRDN Viridian Therapeutics Incindustry
- KOD Kodiak Sciences Incindustry
- ADMA ADMA Biologics Incindustry
- XNCR Xencor Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- MEDCL.PA Medincell SAindustry
- RPRX Royalty Pharma Plcindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry
- EXEL Exelixis Incindustry
- KYMR Kymera Therapeutics Incindustry